Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a trial. "This finding is important because it represents a targeted and relatively nontoxic and nonchemotherapeutic treatment," said Martin S. Tallman, MD, Hairy cell leukemia (HCL), a rare type of leukemia, manifests when bone marrow produces too many lymphocytes, a type of white blood cell. The disease can be treated with the chemotherapy drug Cladribine either with or without the anti-CD20 monoclonal antibody Rituximab. Unfortunately, 30 to 40 percent of patients will still relapse. In the case of relapsed...